COMy 2019 | Beyond KarMMa-2: agents targeting BCMA in MM

Andrew Yee

Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the KarMMa-2 trial (NCT03601078) and further trials that also targeting BCMA. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video